Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults
Background: Repetitive Transcranial Magnetic Stimulation
rTMS involves focal magnetic stimulation through the scalp without the use of anesthesia. The common placement site is at the dorsolateral prefrontal cortex, the usual dosage is less than 20 Hertz, and the average duration of treatment is 40 minutes daily (usually weekdays) for 2 to 6 weeks. rTMS is not approved by the FDA for treating TRD, however, and availability of this treatment option is currently limited, though improving.
Keywords: FDA approval | duration | repetitive transcranial magnetic stimulation | rTMS | placement site | availability | usual dosage
- Gaynes BN, Lux L, Lloyd S, et al. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Comparative Effectiveness Review No. 33 (Prepared by RTI International–University of North Carolina (RTI-UNC) Evidence-based Practice Center under Contract No. 290-02-0016-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC056-EF. Available at: http://www.effectivehealthcare.ahrq.gov/trd.cfm.
- Fitzgerald PB, Benitez J, de Castella A, et al. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am J Psychiatry 2006 Jan;163(1):88-94.
- Rossi S, Hallett M, Rossini PM, et al, for the Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009 Dec;120(12):2008-39.
Your slide tray is being processed.